Eledon Pharmaceuticals, Inc. (ELDN)
| Market Cap | 260.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.55M |
| Shares Out | 59.74M |
| EPS (ttm) | -2.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,752,871 |
| Open | 4.200 |
| Previous Close | 4.220 |
| Day's Range | 3.950 - 4.420 |
| 52-Week Range | 1.430 - 5.540 |
| Beta | 0.76 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+266.97%) |
| Earnings Date | Nov 12, 2024 |
About ELDN
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ELDN stock is "Strong Buy" and the 12-month stock price forecast is $16.0.
News
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive ini...
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart
Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, u...
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its commo...
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose cont...
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment)...
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial a...
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company's management team will be hosting one-on-one meetings at the L...
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 po...
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rej...
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taki...
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports...
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the ...
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company's ong...
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
Historic kidney xenotransplantation procedure conducted at Massachusetts General Hospital Tegoprubart administration has now been used investigationally to prevent rejection in both kidney and heart p...
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company's Compensation Committee granted 42,500 restricted stock units...
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-toler...
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
IRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ ...
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m 2 at all r...
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D.
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
IRVINE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company will present a poster at the American Society of Nephrology's ...
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D.